CYTK · Cytokinetics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.36M | - | $1.94M | $66.77M | $1.58M | - | $463.0K | $249.0K | $835.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $95.53M | - | $99.23M | $112.55M | $99.84M | - | $84.61M | $79.60M | $81.57M | - |
| SG&A | $57.37M | - | $69.46M | $65.72M | $57.37M | - | $56.65M | $50.82M | $45.50M | - |
| Total Operating Expenses | $202.97M | - | $168.69M | $178.28M | $157.21M | - | $141.26M | $130.42M | $127.07M | - |
| D&A | $3.38M | - | - | - | $2.30M | - | - | - | $2.33M | - |
| Operating Income | ($183.62M) | - | ($166.75M) | ($111.51M) | ($155.63M) | - | ($140.80M) | ($130.17M) | ($126.23M) | - |
| Interest Expense | - | - | $11.35M | $11.08M | - | - | $8.93M | $12.73M | $7.10M | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($206.03M) | - | ($306.18M) | ($134.37M) | ($161.38M) | - | ($160.54M) | ($143.32M) | ($135.64M) | - |
| EPS - Basic | ($1.67) | - | ($2.55) | ($1.12) | ($1.36) | - | ($1.36) | ($1.31) | ($1.33) | - |
| EPS - Diluted | ($1.67) | - | ($2.55) | ($1.12) | ($1.36) | - | ($1.36) | ($1.31) | ($1.33) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $129.84M | $122.52M | $225.47M | $74.94M | $73.68M | $94.86M | $46.89M | $190.14M | $119.98M | $113.02M |
| Accounts Receivable | $6.83M | $17.76M | $1.81M | $8.41M | $2.01M | $16.65M | $244.0K | $0 | $834.0K | $1.28M |
| Inventory | $0 | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $24.71M | $22.34M | $22.08M | $16.23M | $13.94M | $20.37M | $11.58M | $9.47M | $12.97M | $21.51M |
| Current Assets | $839.47M | $916.98M | $977.35M | $886.54M | $956.05M | $1.11B | $1.02B | $1.07B | $638.70M | $628.05M |
| Total Assets | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808.08M | $824.32M |
| Current Liabilities | $199.19M | $202.45M | $142.14M | $131.06M | $159.73M | $179.67M | $109.81M | $102.78M | $88.86M | $102.68M |
| Long-term Debt | $247.21M | $246.38M | $158.75M | $159.06M | $92.03M | $93.23M | $93.02M | $92.83M | $56.82M | $58.38M |
| Total Liabilities | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | $1.21B |
| Stockholders' Equity | ($826.57M) | ($659.63M) | ($521.12M) | ($368.72M) | ($266.41M) | ($135.37M) | ($13.91M) | $108.55M | ($396.16M) | ($386.32M) |
| Retained Earnings | ($3.69B) | ($3.49B) | ($3.30B) | ($3.00B) | ($2.86B) | ($2.70B) | ($2.55B) | ($2.39B) | ($2.25B) | ($2.11B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($145.46M) | - | - | - | ($131.62M) | - | - | - | ($129.51M) | - |
| Investing Cash Flow | $145.49M | - | - | - | $105.96M | - | - | - | $32.64M | - |
| Financing Cash Flow | $7.77M | - | - | - | $4.75M | - | - | - | $103.79M | - |
| CapEx | $5.93M | - | - | - | $5.66M | - | - | - | $0 | - |
| Free Cash Flow | ($151.39M) | - | - | - | ($137.28M) | - | - | - | ($129.51M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -948.7% | - | -8613.4% | -167.0% | -9856.3% | - | -30410.6% | -52277.9% | -15118.0% | - |
| EBITDA margin | -931.2% | - | - | - | -9710.6% | - | - | - | -14838.8% | - |
| Net margin | -1064.5% | - | -15815.0% | -201.2% | -10220.1% | - | -34674.9% | -57557.4% | -16244.7% | - |
| Free cash flow margin | -782.2% | - | - | - | -8694.2% | - | - | - | -15509.8% | - |
| FCF / Net income | 0.73 | - | - | - | 0.85 | - | - | - | 0.95 | - |
| R&D / Revenue | 493.5% | - | 5125.7% | 168.6% | 6323.1% | - | 18274.7% | 31966.7% | 9768.9% | - |
| SG&A / Revenue | 296.4% | - | 3587.7% | 98.4% | 3633.2% | - | 12235.9% | 20411.2% | 5449.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -16.2% | - | -21.3% | -11.0% | -12.8% | - | -11.2% | -9.4% | -16.8% | - |
| Return on equity | 24.9% | - | 58.8% | 36.4% | 60.6% | - | 1154.1% | -132.0% | 34.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.21 | 4.53 | 6.88 | 6.76 | 5.99 | 6.17 | 9.28 | 10.39 | 7.19 | 6.12 |
| Quick ratio | 4.21 | 4.53 | 6.88 | 6.76 | 5.99 | 6.17 | 9.28 | 10.39 | 7.19 | 6.12 |
| Cash ratio | 0.65 | 0.61 | 1.59 | 0.57 | 0.46 | 0.53 | 0.43 | 1.85 | 1.35 | 1.10 |
| Leverage | ||||||||||
| Debt / Equity | -0.30 | -0.37 | -0.30 | -0.43 | -0.35 | -0.69 | -6.69 | 0.86 | -0.14 | -0.15 |
| Debt / Assets | 0.19 | 0.17 | 0.11 | 0.13 | 0.07 | 0.07 | 0.06 | 0.06 | 0.07 | 0.07 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -14.7x | -10.1x | - | - | -15.8x | -10.2x | -17.8x | - |
| Equity multiplier | -1.54 | -2.16 | -2.76 | -3.32 | -4.74 | -10.35 | -103.23 | 14.04 | -2.04 | -2.13 |
| Liabilities / Assets | 1.65 | 1.46 | 1.36 | 1.30 | 1.21 | 1.10 | 1.01 | 0.93 | 1.49 | 1.47 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.00 | 0.05 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 129d | - | 341d | 46d | 465d | - | 192d | 0d | 365d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | 0.1x | - | - |
| P / S | 0.4x | - | 3.4x | 0.1x | 3.0x | - | 13.4x | 23.8x | 8.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1125.8% | - | 318.1% | 26714.9% | 89.1% | - | 22.5% | -71.3% | -81.9% | - |
| Revenue CAGR (3y) | 61.3% | - | -8.4% | -9.1% | 11.2% | - | -56.0% | -55.6% | -49.7% | - |
| Revenue CAGR (5y) | 24.2% | - | -45.9% | 79.4% | -16.2% | - | -46.6% | -47.5% | -37.1% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -18.0% | - | -18.4% | 14.3% | -23.3% | - | -15.2% | -6.7% | -1.4% | - |
| Net income growth (YoY) | -27.7% | - | -90.7% | 6.2% | -19.0% | - | -24.0% | -11.4% | -3.3% | - |
| EPS growth (YoY) | -22.8% | - | -87.5% | 14.5% | -2.3% | - | -0.7% | 2.2% | 3.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -10.3% | - | - | - | -6.0% | - | - | - | -5.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -210.3% | -387.3% | -3646.1% | - | 32.8% | 65.0% | 96.8% | - | -73.0% | -258.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$88.04M totalLicense And Milestone Revenues$79.35M · 90.1%
Collaboration Revenues$8.69M · 9.9%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CYTOKINETICS INC against the 5 most active filers in the same SIC group.